Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Methotrexate in Chronic Severe Asthma
NCT02124226Phase 3Unknown
- Sponsor
- University of Catania
- Start
- Dec 2021
- Primary completion
- Apr 2022
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Methotrexate with Matched placebo (2 arms). Primary endpoint: At least 50% reduction in total dosage of GINA step 5 medications at 80 weeks. Status: unknown.
02
Drugs
methotrexate
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02124226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02124226.